Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
Covered in this story
What has happened since
- Gilead Sciences is up 6.7% since this was published, 42 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $GILD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Gilead Sciences →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.